Market Cap
US$1.7b
Last Updated
2021/01/23 23:24 UTC
Data Sources
Company Financials +
Executive Summary
uniQure N.V., a gene therapy company, engages in the development and commercialization of treatments for patients suffering from genetic and other diseases in the Netherlands. More Details
Rewards
Risk Analysis
Currently unprofitable and not forecast to become profitable over the next 3 years
Snowflake Analysis
Adequate balance sheet with concerning outlook.
Similar Companies
Share Price & News
How has uniQure's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: QURE is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: QURE's weekly volatility (8%) has been stable over the past year.
Market Performance
7 Day Return
4.6%
QURE
1.8%
US Biotechs
2.3%
US Market
1 Year Return
-36.8%
QURE
45.9%
US Biotechs
23.8%
US Market
Return vs Industry: QURE underperformed the US Biotechs industry which returned 45.9% over the past year.
Return vs Market: QURE underperformed the US Market which returned 23.7% over the past year.
Shareholder returns
| QURE | Industry | Market | |
|---|---|---|---|
| 7 Day | 4.6% | 1.8% | 2.3% |
| 30 Day | 3.0% | 6.7% | 4.8% |
| 90 Day | -7.9% | 24.9% | 14.5% |
| 1 Year | -36.8%-36.8% | 48.3%45.9% | 26.6%23.8% |
| 3 Year | 102.5%102.5% | 23.3%16.6% | 45.0%35.4% |
| 5 Year | 115.4%115.4% | 58.9%46.7% | 126.2%101.0% |
Long-Term Price Volatility Vs. Market
How volatile is uniQure's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall St
Is uniQure (NASDAQ:QURE) Using Debt Sensibly?1 month ago | Simply Wall St
Is uniQure N.V. (NASDAQ:QURE) Trading At A 30% Discount?2 months ago | Simply Wall St
Bullish: Analysts Just Made A Noticeable Upgrade To Their uniQure N.V. (NASDAQ:QURE) ForecastsValuation
Is uniQure undervalued compared to its fair value and its price relative to the market?
7.66x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: QURE ($39.26) is trading above our estimate of fair value ($16.32)
Significantly Below Fair Value: QURE is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: QURE is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: QURE is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate QURE's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: QURE is overvalued based on its PB Ratio (7.7x) compared to the US Biotechs industry average (4.4x).
Next Steps
Future Growth
How is uniQure forecast to perform in the next 1 to 3 years based on estimates from 18 analysts?
1.8%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: QURE is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: QURE is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: QURE is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: QURE's revenue (19.6% per year) is forecast to grow faster than the US market (10.6% per year).
High Growth Revenue: QURE's revenue (19.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: QURE is forecast to be unprofitable in 3 years.
Next Steps
Past Performance
How has uniQure performed over the past 5 years?
-13.2%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: QURE is currently unprofitable.
Growing Profit Margin: QURE is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: QURE is unprofitable, and losses have increased over the past 5 years at a rate of 13.2% per year.
Accelerating Growth: Unable to compare QURE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: QURE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-10.3%).
Return on Equity
High ROE: QURE has a negative Return on Equity (-72.73%), as it is currently unprofitable.
Next Steps
Financial Health
How is uniQure's financial position?
Financial Position Analysis
Short Term Liabilities: QURE's short term assets ($287.4M) exceed its short term liabilities ($33.4M).
Long Term Liabilities: QURE's short term assets ($287.4M) exceed its long term liabilities ($89.3M).
Debt to Equity History and Analysis
Debt Level: QURE's debt to equity ratio (15.6%) is considered satisfactory.
Reducing Debt: QURE's debt to equity ratio has increased from 12.6% to 15.6% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: QURE has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if QURE has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Next Steps
Dividend
What is uniQure current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate QURE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate QURE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if QURE's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if QURE's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of QURE's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
3.4yrs
Average management tenure
CEO
Matt Kapusta (48 yo)
4.08yrs
Tenure
US$4,719,955
Compensation
Mr. Matthew Craig Kapusta, also known as Matt, has been the Chief Executive Officer of uniQure N.V. since December 19, 2016 and serves as its Chief Financial Officer. Mr. Kapusta served as a Chief Financia...
CEO Compensation Analysis
Compensation vs Market: Matt's total compensation ($USD4.72M) is about average for companies of similar size in the US market ($USD3.86M).
Compensation vs Earnings: Matt's compensation has increased whilst the company is unprofitable.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, CFO & Executive Director | 4.08yrs | US$4.72m | 0.46% $ 8.0m | |
| Executive Vice President of Operations | 1.42yrs | US$1.35m | 0.012% $ 215.2k | |
| Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany | 6.42yrs | no data | no data | |
| Chief Accounting Officer | 3.42yrs | no data | 0.095% $ 1.7m | |
| Chief Legal Officer | 2.83yrs | no data | no data | |
| Chief Communications Officer | 4.58yrs | US$1.22m | no data | |
| Business Development Director | 12.58yrs | no data | no data | |
| Chief Human Resources Officer | 0.42yr | no data | no data | |
| Chief Business Officer | 4.5yrs | US$1.32m | no data | |
| President of Research & Development | 0.33yr | no data | no data | |
| Vice President of Global Medical Affairs | no data | no data | no data |
3.4yrs
Average Tenure
52yo
Average Age
Experienced Management: QURE's management team is considered experienced (3.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, CFO & Executive Director | 4.08yrs | US$4.72m | 0.46% $ 8.0m | |
| Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany | 6.42yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Chairman | 4.33yrs | US$282.96k | 0.013% $ 235.8k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Non-Executive Director | 4.58yrs | US$255.81k | 0.032% $ 554.7k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Non-Executive Director | 3.33yrs | US$247.91k | 0.013% $ 235.8k | |
| Independent Non-Executive Director | 3.33yrs | US$255.41k | 0.013% $ 235.8k | |
| Independent Non-Executive Director | 7.5yrs | US$230.01k | 0.0054% $ 95.2k | |
| Non-Executive Member | 2.25yrs | US$1.95m | 0.016% $ 287.1k |
4.5yrs
Average Tenure
58yo
Average Age
Experienced Board: QURE's board of directors are considered experienced (4.5 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.1%.
Top Shareholders
Company Information
uniQure N.V.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: uniQure N.V.
- Ticker: QURE
- Exchange: NasdaqGS
- Founded: 1998
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$1.747b
- Shares outstanding: 44.49m
- Website: https://www.uniqure.com
Number of Employees
Location
- uniQure N.V.
- Paasheuvelweg 25a
- Amsterdam
- Noord-Holland
- 1105 BP
- Netherlands
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| QURE | NasdaqGS (Nasdaq Global Select) | Yes | Ordinary Shares | US | USD | Feb 2014 |
| UQ1 | DB (Deutsche Boerse AG) | Yes | Ordinary Shares | DE | EUR | Feb 2014 |
| 0EE0 | LSE (London Stock Exchange) | Yes | Ordinary Shares | GB | USD | Feb 2014 |
Biography
uniQure N.V., a gene therapy company, engages in the development and commercialization of treatments for patients suffering from genetic and other diseases in the Netherlands. Its lead program is Etranacog...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/01/23 23:24 |
| End of Day Share Price | 2021/01/22 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.